• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨形态发生蛋白受体 ALK2 的结构及其在进行性骨化性纤维发育不良中的意义。

Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.

机构信息

Structural Genomics Consortium, University of Oxford, Oxford OX3 7DQ, United Kingdom.

出版信息

J Biol Chem. 2012 Oct 26;287(44):36990-8. doi: 10.1074/jbc.M112.365932. Epub 2012 Sep 12.

DOI:10.1074/jbc.M112.365932
PMID:22977237
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3481300/
Abstract

Bone morphogenetic protein (BMP) receptor kinases are tightly regulated to control development and tissue homeostasis. Mutant receptor kinase domains escape regulation leading to severely degenerative diseases and represent an important therapeutic target. Fibrodysplasia ossificans progressiva (FOP) is a rare but devastating disorder of extraskeletal bone formation. FOP-associated mutations in the BMP receptor ALK2 reduce binding of the inhibitor FKBP12 and promote leaky signaling in the absence of ligand. To establish structural mechanisms of receptor regulation and to address the effects of FOP mutation, we determined the crystal structure of the cytoplasmic domain of ALK2 in complex with the inhibitors FKBP12 and dorsomorphin. FOP mutations break critical interactions that stabilize the inactive state of the kinase, thereby facilitating structural rearrangements that diminish FKBP12 binding and promote the correct positioning of the glycine-serine-rich loop and αC helix for kinase activation. The balance of these effects accounts for the comparable activity of R206H and L196P. Kinase activation in the clinically benign mutant L196P is far weaker than R206H but yields equivalent signals due to the stronger interaction of FKBP12 with R206H. The presented ALK2 structure offers a valuable template for the further design of specific inhibitors of BMP signaling.

摘要

骨形态发生蛋白(BMP)受体激酶受到严格调控,以控制发育和组织内稳态。突变的受体激酶结构域逃脱了调控,导致严重的退行性疾病,是一个重要的治疗靶点。骨纤维结构不良进展性(FOP)是一种罕见但破坏性的骨外骨骼形成障碍。FOP 相关的 BMP 受体 ALK2 突变减少了抑制剂 FKBP12 的结合,并在没有配体的情况下促进渗漏信号。为了建立受体调控的结构机制,并解决 FOP 突变的影响,我们确定了与抑制剂 FKBP12 和 Dorsomorphin 复合物的 ALK2 细胞质结构域的晶体结构。FOP 突变破坏了稳定激酶无活性状态的关键相互作用,从而促进了结构重排,减少了 FKBP12 的结合,并促进了富含甘氨酸-丝氨酸的环和 αC 螺旋的正确定位,以激活激酶。这些效应的平衡解释了 R206H 和 L196P 具有相当的活性。临床上良性突变 L196P 的激酶激活远弱于 R206H,但由于 FKBP12 与 R206H 的相互作用更强,产生了等效的信号。所呈现的 ALK2 结构为进一步设计 BMP 信号特异性抑制剂提供了有价值的模板。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7641/3481300/98cc879c4111/zbc0461228690006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7641/3481300/20f876d1e20f/zbc0461228690001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7641/3481300/ca7e0fffec8c/zbc0461228690002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7641/3481300/cf8ec42a2671/zbc0461228690003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7641/3481300/784df2ddaa7c/zbc0461228690004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7641/3481300/1cc7339a5b9c/zbc0461228690005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7641/3481300/98cc879c4111/zbc0461228690006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7641/3481300/20f876d1e20f/zbc0461228690001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7641/3481300/ca7e0fffec8c/zbc0461228690002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7641/3481300/cf8ec42a2671/zbc0461228690003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7641/3481300/784df2ddaa7c/zbc0461228690004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7641/3481300/1cc7339a5b9c/zbc0461228690005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7641/3481300/98cc879c4111/zbc0461228690006.jpg

相似文献

1
Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.骨形态发生蛋白受体 ALK2 的结构及其在进行性骨化性纤维发育不良中的意义。
J Biol Chem. 2012 Oct 26;287(44):36990-8. doi: 10.1074/jbc.M112.365932. Epub 2012 Sep 12.
2
ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.ALK2 R206H 突变与进行性骨化性纤维发育不良相关,赋予 BMP Ⅰ型受体组成型活性,并使间充质细胞对 BMP 诱导的成骨细胞分化和骨形成敏感。
J Bone Miner Res. 2010 Jun;25(6):1208-15. doi: 10.1359/jbmr.091110.
3
A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H.ALK2 中的一种新型突变 L196P 在最良性的纤维发育不良性骨化性进展病例中被发现,其激活 BMP 特异性细胞内信号与典型突变 R206H 相当。
Biochem Biophys Res Commun. 2011 Apr 1;407(1):213-8. doi: 10.1016/j.bbrc.2011.03.001. Epub 2011 Mar 4.
4
A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor.在一名进行性骨化性纤维发育不良患者中发现的ALK2独特突变G356D是一种中度激活的BMP I型受体。
Biochem Biophys Res Commun. 2008 Dec 19;377(3):905-9. doi: 10.1016/j.bbrc.2008.10.093. Epub 2008 Oct 24.
5
Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva.成骨不全性骨纤维发育不良 ACVR1(R206H)突变的分子后果。
J Biol Chem. 2010 Jul 16;285(29):22542-53. doi: 10.1074/jbc.M109.094557. Epub 2010 May 12.
6
Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva.组成性激活的ALK2和增加的SMAD1/5协同诱导进行性骨化性纤维发育不良中的骨形态发生蛋白信号传导。
J Biol Chem. 2009 Mar 13;284(11):7149-56. doi: 10.1074/jbc.M801681200. Epub 2008 Aug 6.
7
Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.FKBP12 和 II 型 BMP 受体对与遗传疾病相关的 ALK2 激活突变体信号转导的影响。
Bone. 2018 Jun;111:101-108. doi: 10.1016/j.bone.2018.03.015. Epub 2018 Mar 15.
8
Reduced GS Domain Serine/Threonine Requirements of Fibrodysplasia Ossificans Progressiva Mutant Type I BMP Receptor ACVR1 in the Zebrafish.成纤维细胞生长因子受体 1 型突变型骨化性纤维发育不良 BMP 受体在斑马鱼中 GS 结构域丝氨酸/苏氨酸需求减少。
J Bone Miner Res. 2023 Sep;38(9):1364-1385. doi: 10.1002/jbmr.4869. Epub 2023 Jul 17.
9
Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.激活素受体样激酶2(Alk2)在进行性骨化性纤维发育不良的异位软骨内骨化过程中调节早期软骨形成命运。
Stem Cells. 2014 May;32(5):1289-300. doi: 10.1002/stem.1633.
10
In vitro analyses of the dysregulated R206H ALK2 kinase-FKBP12 interaction associated with heterotopic ossification in FOP.成纤维细胞生长因子受体 2 相关激活素受体样激酶 2(ALK2)R206H 激酶- FKBP12 相互作用失调的体外分析与 FOP 中的异位骨化有关。
Cells Tissues Organs. 2011;194(2-4):291-5. doi: 10.1159/000324230. Epub 2011 Apr 28.

引用本文的文献

1
Mechanism and cellular actions of the potent AMPK inhibitor BAY-3827.强效AMPK抑制剂BAY-3827的作用机制及细胞效应
Sci Adv. 2025 Aug 22;11(34):eadx2434. doi: 10.1126/sciadv.adx2434.
2
PI3Kα inhibition blocks osteochondroprogenitor specification and the hyper-inflammatory response to prevent heterotopic ossification.PI3Kα抑制可阻断骨软骨祖细胞的特化及过度炎症反应,从而预防异位骨化。
Elife. 2025 Jun 17;12:RP91779. doi: 10.7554/eLife.91779.
3
Advancements in mechanisms and drug treatments for fibrodysplasia ossificans progressiva.

本文引用的文献

1
Promiscuity and specificity in BMP receptor activation.BMP 受体激活中的混杂性和特异性。
FEBS Lett. 2012 Jul 4;586(14):1846-59. doi: 10.1016/j.febslet.2012.02.043. Epub 2012 Mar 8.
2
Hyperactive BMP signaling induced by ALK2(R206H) requires type II receptor function in a Drosophila model for classic fibrodysplasia ossificans progressiva.ALK2(R206H) 引起的 BMP 信号过度活跃需要 II 型受体功能,这在经典型纤维发育不良性骨化性纤维瘤的果蝇模型中得到了证实。
Dev Dyn. 2012 Jan;241(1):200-14. doi: 10.1002/dvdy.22779.
3
Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1.
进行性骨化性纤维发育不良的发病机制及药物治疗进展
J Zhejiang Univ Sci B. 2025 Apr 23;26(4):317-332. doi: 10.1631/jzus.B2300779.
4
Bone morphogenetic protein (BMP) signaling determines neuroblastoma cell fate and sensitivity to retinoic acid.骨形态发生蛋白(BMP)信号决定神经母细胞瘤细胞的命运以及对视黄酸的敏感性。
Nat Commun. 2025 Feb 28;16(1):2036. doi: 10.1038/s41467-025-57185-y.
5
OsFKBP12 transduces the sucrose signal from OsNIN8 to the OsTOR pathway in a loosely binding manner for cell division.OsFKBP12以一种松散结合的方式将蔗糖信号从OsNIN8传递到OsTOR途径,以促进细胞分裂。
iScience. 2024 Dec 9;28(1):111555. doi: 10.1016/j.isci.2024.111555. eCollection 2025 Jan 17.
6
Molecular Developmental Biology of Fibrodysplasia Ossificans Progressiva: Measuring the Giant by Its Toe.成骨不全性骨纤维发育不良的分子发育生物学:以小见大。
Biomolecules. 2024 Aug 15;14(8):1009. doi: 10.3390/biom14081009.
7
Discovery of Two Highly Selective Structurally Orthogonal Chemical Probes for Activin Receptor-like Kinases 1 and 2.发现两种针对激活素受体样激酶1和2的高选择性结构正交化学探针。
J Med Chem. 2024 Aug 8;67(15):12632-12659. doi: 10.1021/acs.jmedchem.4c00629. Epub 2024 Jul 18.
8
The HIF-1α and mTOR Pathways Amplify Heterotopic Ossification.HIF-1α 和 mTOR 通路放大异位骨化。
Biomolecules. 2024 Jan 24;14(2):147. doi: 10.3390/biom14020147.
9
The Activation of the Fibrodysplasia Ossificans Progressiva-Inducing ALK2-R206H Mutant Depends on the Distinct Homo-Oligomerization Patterns of ACVR2B and ACVR2A.ALK2-R206H 突变型纤维发育不良性骨化进展激活依赖于 ACVR2B 和 ACVR2A 的独特同源寡聚化模式。
Cells. 2024 Jan 25;13(3):221. doi: 10.3390/cells13030221.
10
FK506 bypasses the effect of erythroferrone in cancer cachexia skeletal muscle atrophy.FK506 可绕过红细胞生成素在癌症恶病质骨骼肌萎缩中的作用。
Cell Rep Med. 2023 Dec 19;4(12):101306. doi: 10.1016/j.xcrm.2023.101306. Epub 2023 Dec 4.
进行性骨化性纤维发育不良:ACVR1 中独特的错义突变(c.974G>C,p.G325A)导致中年发病的异位骨化。
J Bone Miner Res. 2012 Mar;27(3):729-37. doi: 10.1002/jbmr.1473.
4
In vitro analyses of the dysregulated R206H ALK2 kinase-FKBP12 interaction associated with heterotopic ossification in FOP.成纤维细胞生长因子受体 2 相关激活素受体样激酶 2(ALK2)R206H 激酶- FKBP12 相互作用失调的体外分析与 FOP 中的异位骨化有关。
Cells Tissues Organs. 2011;194(2-4):291-5. doi: 10.1159/000324230. Epub 2011 Apr 28.
5
A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H.ALK2 中的一种新型突变 L196P 在最良性的纤维发育不良性骨化性进展病例中被发现,其激活 BMP 特异性细胞内信号与典型突变 R206H 相当。
Biochem Biophys Res Commun. 2011 Apr 1;407(1):213-8. doi: 10.1016/j.bbrc.2011.03.001. Epub 2011 Mar 4.
6
Conversion of vascular endothelial cells into multipotent stem-like cells.血管内皮细胞向多能干细胞样细胞的转化。
Nat Med. 2010 Dec;16(12):1400-6. doi: 10.1038/nm.2252. Epub 2010 Nov 21.
7
A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date.迄今为止报道的最良性纤维发育不良性骨化进展变异病例中,在甘氨酸/丝氨酸丰富区发现了一种新型的 ACVR1 突变。
Bone. 2011 Mar 1;48(3):654-8. doi: 10.1016/j.bone.2010.10.164. Epub 2010 Oct 29.
8
Inherited human diseases of heterotopic bone formation.遗传性异位骨形成的人类疾病。
Nat Rev Rheumatol. 2010 Sep;6(9):518-27. doi: 10.1038/nrrheum.2010.122. Epub 2010 Aug 10.
9
Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva.成骨不全性骨纤维发育不良 ACVR1(R206H)突变的分子后果。
J Biol Chem. 2010 Jul 16;285(29):22542-53. doi: 10.1074/jbc.M109.094557. Epub 2010 May 12.
10
ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.ALK2 R206H 突变与进行性骨化性纤维发育不良相关,赋予 BMP Ⅰ型受体组成型活性,并使间充质细胞对 BMP 诱导的成骨细胞分化和骨形成敏感。
J Bone Miner Res. 2010 Jun;25(6):1208-15. doi: 10.1359/jbmr.091110.